TMB is associated with the prognosis of egfr-mutated non-small cell lung cancer in Xuanwei, China

Study on the prognostic characteristics and biomarkers of lung cancer in Xuanwei Patients. A retrospective analysis was conducted on the genetic data of 261 NSCLC patients, as well as the prognostic data of 133 patients. The relationship between prognosis and EGFR mutations in the Xuanwei and non Xuanwei cohorts was compared and analyzed. The superior progression-free survival (PFS) in Xuanwei patients was primarily observed in those with EGFR-mutated tumors (<i>p</i> &lt; 0.05). Further analysis of accompanying mutations and TMB levels revealed an association between high TMB and a favorable prognosis in EGFR-mutated Xuanwei NSCLC. Xuanwei lung cancer differs from non Xuanwei patients in terms of prognosis and tumor mutation burden, and further research should be conducted.

宣威地区肺癌患者预后特征及生物标志物研究。对261例非小细胞肺癌（Non-Small Cell Lung Cancer, NSCLC）患者的基因数据及133例患者的预后数据进行回顾性分析。比较分析了宣威队列与非宣威队列中预后与表皮生长因子受体（EGFR）突变的关系。宣威患者中更优的无进展生存期（Progression-Free Survival, PFS）主要见于携带EGFR突变肿瘤的患者（<i>p</i>＜0.05）。对伴随突变及肿瘤突变负荷（Tumor Mutation Burden, TMB）水平的进一步分析显示，在EGFR突变的宣威非小细胞肺癌患者中，高TMB与良好预后相关。宣威肺癌在预后及肿瘤突变负荷方面与非宣威患者存在差异，需开展进一步研究。